Strs Ohio Has $55.25 Million Stock Position in CVS Health Corporation $CVS

Key Points

• Strs Ohio reduced its CVS Health stake by 13.4% in the first quarter, selling 118,543 shares and leaving it with 769,277 shares worth about $55.25 million.
• Wall Street remains broadly positive on CVS, with multiple firms raising price targets and the stock carrying a consensus “Moderate Buy” rating. Analysts currently see a consensus target price of $101.28.
• CVS reported strong quarterly results, beating earnings and revenue estimates, and raised its FY2026 EPS guidance to a range of 7.30 to 7.50.

Strs Ohio cut its position in CVS Health Corporation (NYSE:CVS - Free Report) by 13.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 769,277 shares of the pharmacy operator's stock after selling 118,543 shares during the period. Strs Ohio owned 0.06% of CVS Health worth $55,249,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Keybank National Association OH grew its position in CVS Health by 12.4% during the 1st quarter. Keybank National Association OH now owns 96,324 shares of the pharmacy operator's stock worth $6,918,000 after acquiring an additional 10,596 shares during the last quarter. Heritage Investors Management Corp boosted its stake in CVS Health by 2.6% in the first quarter. Heritage Investors Management Corp now owns 9,031 shares of the pharmacy operator's stock worth $649,000 after purchasing an additional 225 shares in the last quarter. Vision Capital Management Inc. grew its holdings in shares of CVS Health by 2.0% during the first quarter. Vision Capital Management Inc. now owns 48,713 shares of the pharmacy operator's stock worth $3,499,000 after purchasing an additional 974 shares during the last quarter. Essex Financial Services Inc. grew its holdings in shares of CVS Health by 6.9% during the first quarter. Essex Financial Services Inc. now owns 21,384 shares of the pharmacy operator's stock worth $1,536,000 after purchasing an additional 1,389 shares during the last quarter. Finally, Financial Life Planners acquired a new stake in shares of CVS Health in the first quarter valued at $48,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on CVS. Leerink Partners reiterated an "outperform" rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Wells Fargo & Company boosted their target price on shares of CVS Health from $102.00 to $103.00 and gave the stock an "overweight" rating in a research note on Friday, May 8th. TD Cowen upped their target price on shares of CVS Health from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Bank of America raised their price target on shares of CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a report on Monday, June 22nd. Finally, Truist Financial boosted their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a "buy" rating in a research report on Monday, June 1st. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $101.28.

Insiders Place Their Bets

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the company's stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last ninety days. Company insiders own 0.85% of the company's stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts continue to highlight CVS Health’s strong history of earnings beats and say the company has a good setup to potentially top estimates again in its next report, which can support sentiment ahead of results. Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: CVS Health is expanding its public-health profile through America250 community events, menopause and preventive-care initiatives, and support for Medicare obesity drug access, reinforcing its role as a broader healthcare services provider. CVS Health (CVS) Takes A Leading Role In America250 Community Health Events
• Positive Sentiment: The CVS Health Foundation announced a $1 million investment in Rhode Island nonprofits focused on health care, food, housing, and essential services, which may help brand reputation and community ties. CVS Health Foundation Invests $1 Million in Rhode Island Nonprofits Tackling Community Health Needs
• Positive Sentiment: Coverage around Medicare obesity drug coverage notes CVS and Walmart are helping seniors navigate the new benefit, highlighting CVS’s value in Medicare-related patient support. Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
• Neutral Sentiment: Some commentary says CVS stock may already be fully valued, with strong returns and rich earnings limiting upside if fundamentals do not accelerate further. CVS Health (CVS) Stock Looks Fully Valued With Strong Returns And Rich Earnings
• Neutral Sentiment: CVS leadership and the company’s data-and-analytics expertise remain in the spotlight, including a board appointment at Choice Hotels, but this is unlikely to materially move the stock. Choice Hotels International Appoints Artificial Intelligence Leader Ali Keshavarz to Board of Directors
• Negative Sentiment: A nationwide recall of CVS Health hemorrhoidal wipes is a modest headline risk that could weigh on sentiment due to product quality and consumer safety concerns. CVS Health hemorrhoidal wipes sold nationwide recalled
• Negative Sentiment: New reports that CVS, along with other major insurers, denied post-hospital care at high rates could increase regulatory and reputational pressure on its insurance operations and PBM/Caremark business. UnitedHealth, Humana, CVS Denied Post-Hospital Care At Some Of The Highest Rates
• Negative Sentiment: Investors are also watching fresh scrutiny of CVS Health’s Caremark pharmacy benefit manager operations, which could add uncertainty despite the company’s upbeat earnings outlook. How Investors Are Reacting To CVS Health (CVS) Earnings Optimism Amid New PBM Scrutiny and Care Initiatives

CVS Health Stock Performance

Shares of NYSE:CVS opened at $104.74 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $106.15. The stock has a market capitalization of $133.64 billion, a P/E ratio of 46.14, a P/E/G ratio of 1.03 and a beta of 0.61. The business has a 50-day moving average price of $93.99 and a two-hundred day moving average price of $83.13.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.